Shares of WuXi AppTec and WuXi Biologics are closing in on pre-Biosecure Act levels now that the legislation that sought to rein in China CDMOs and genomics companies appears to have faded away. Read my latest in BioCentury: https://www.biocentury.com/article/655397
Comments